Kenya is set to receive Lenacapavir injectable HIV preventive drug in January 2026 after the World Health Organization(WHO) approved its rollout.
According to WHO, 1.3 million people acquired the virus back in 2024 and most of them were adolescent girls and young women.
-
EPRA increases pump prices for Super Petrol, Diesel and Kerosene
-
Mombasa couple arrested for sexually exploiting own children
Because of the statistics, they approved the twice a year injectable drug meant to prevent the contraction of the virus.
“1.3 million people acquired HIV in 2024 alone, including thousands of adolescent girls and young women.
Today, in a landmark move towards HIV prevention, WHO recommends twice-yearly injectable lenacapavir as pre-exposure prophylaxis (PrEP) to protect people at risk of HIV.” said WHO
Even though the drug has recorded success during its trial, questions have been asked over its pricing and why Kenyans are among the first countries to receive such new drugs.
